Several readers will be interested in looking through a new article that deals with the recommendations from the Prostate Cancer Clinical Trials Working Group 3 on the development of clinical trials of new drugs to treat castration-resistant prostate cancer (CRPC).
The article by Geethakumari et al. is published in the journal Oncology. It deals in particular with evolutions in our understanding of the biology of CRPC, how acquired resistance mechanisms develop over time, and the identifciation of emerging therapeutic targets which may lead to the development, clinical trial, and approval of new classes of therapeutic agent.
You do need to register to be able to see the full text of this article, but there is no charge for registration.
Filed under: Drugs in development, Management, Treatment | Tagged: castration-resistant, CRPC, future, metastatic, trials |
THE "NEW" PROSTATE CANCER INFOLINK 
Leave a Reply